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Of all the lipids routinely measured in clinical practice, serum 
triglycerides (TGs) are the most variable and can increase more than 
50-fold from baseline. Ideally, fasting TGs should be <1.7 mmol/L, but 
TGs can reach values of >100.0 mmol/L in some patients. The clinical 
approach to hypertriglyceridaemia varies considerably, depending on 
the degree of elevation and the clinical context. Although there are 
multiple classification schemes for hypertriglyceridaemia, a simple 
and useful scheme is to classify hypertriglyceridaemia of >1.7 - 
<10.0 mmol/L as mild to moderate, while TGs >10.0 mmol/L are 
classified as severe hypertriglyceridaemia.[1]
What are the potential clinical  
consequences of hypertriglyceridaemia? 
The two most important clinical consequences of hypertriglyceri-
daemia are acute pancreatitis and atherosclerotic cardiovascular 
disease (CVD). Severe hypertriglyceridaemia may lead to acute 
pancreatitis.[2] The mechanisms by which hypertriglyceridaemia 
causes pancreatitis are not that well understood, but may relate 
to impairment of capillary perfusion in the pancreas, pancreatic 
cell necrosis and subsequent release and activation of pancreatic 
enzymes. When and if pancreatitis will occur in an individual patient 
is quite unpredictable – some patients may have TGs of >100.0 mmol/L 
and no symptoms, while others develop pancreatitis at much lower 
TG levels. 
Mild-to-moderate hypertriglyceridaemia is an independent 
cardiovascular risk factor. There is still some debate about the exact 
mechanisms by which triglyceride-rich lipoproteins (TGRLs) cause 
atherosclerosis. However, the cholesterol found in these TGRLs is 
likely a major causative factor.[3] This remnant cholesterol can be 
approximated by the following calculation:
 Remnant cholesterol = total cholesterol − high-density lipoprotein 
(HDL) cholesterol − low-density lipoprotein (LDL) cholesterol[4]
The relative risk of CVD from a 1.0 mmol/L increase in TGs ranges 
from 1.14 to 1.80 (dependent on sex and race) after adjustment for 
other risk factors such as HDL cholesterol.[5]
What causes hypertriglyceridaemia?
Hypertriglyceridaemia has multiple and complex causes. Most cases 
are caused by the interaction of multiple genetic factors (polygenic 
aetiology) with environmental factors. The relative importance of the 
genetic and environmental contributions can vary between patients, 
i.e. in some patients environmental factors may be dominant, while in 
others genetic factors may be more prominent. Genetic investigation 
of patients with polygenic hypertriglyceridaemia is difficult because 
of the multitude of genes that may affect TGs. Variants in these genes 
individually have very little effect on TGs, but accumulation of many 
TG-raising variants may lead to hypertriglyceridaemia.[1] A score that 
tallies carrier status for TG-raising alleles at 32 genetic loci has been 
constructed and is higher in patients with hypertriglyceridaemia 
than in normal controls.[6] Genetic complexity is further increased by 
gene variants that lower TGs. From a practical point of view, genetic 
testing of patients with hypertriglyceridaemia is of limited clinical use 
unless a monogenic cause is strongly suspected.
Monogenic hypertriglyceridaemia is usually severe and manifests 
in infancy or early childhood. It is usually inherited in an autosomal 
recessive pattern and is most commonly due to biallelic mutations 
of the lipoprotein lipase (LPL) gene. LPL deficiency has been 
described in all South African (SA) population groups, but is most 
commonly seen in Indians and Afrikaners. Occasionally, patients 
with dysbetalipoproteinaemia, which results from mutations in 
apolipoprotein E (apo E), develop severe hypertriglyceridaemia, 
although the more common phenotype is that of a severe mixed 
hyperlipidaemia with a total cholesterol to triglyceride ratio of 2:1. 
Environmental factors that may contribute to the development 
of hypertriglyceridaemia include lifestyle factors, medical disorders 
and drugs (Table 1). Identification and treatment of these secondary 
factors (where possible) are often key to the management of patients 
with hypertriglyceridaemia. The clinical experience at Groote Schuur 
Hospital Lipid Clinic, Cape Town, SA, is that uncontrolled or 
undiagnosed diabetes is by far the most common secondary factor 
in patients with hypertriglyceridaemia (D J Blom – unpublished 
observation, 2018).
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What clinical clues can help to identify 
patients with hypertriglyceridaemia? 
Mild-to-moderate hypertriglyceridaemia is generally only identified 
on laboratory testing, although its presence should be suspected 
in patients with any of the secondary factors (Table 1). Patients 
with severe hypertriglyceridaemia may develop eruptive or tubo- 
eruptive xanthomata (Fig. 1A and B). Eruptive xanthomata are most 
commonly found around the elbows, knees, buttocks and thighs 
and are usually asymptomatic. Lipaemia retinalis (white to creamy 
appearance of retinal blood vessels) may be visible on fundoscopy. 
Severe hypertriglyceridaemia cannot be excluded if these physical 
signs are absent. Laboratory comments referring to a ‘lipaemic 
specimen’ (Fig. 1C) should be taken seriously, as this may be the 
first clue that a patient has elevated TGs. Lipid screening is often 
commenced with total cholesterol determination only. If the total 
cholesterol is very high, it should always be followed up with a full 
lipogram to detect the patients in whom the very high total cholesterol 
reflects an accumulation of TGRLs rather than LDL particles. 
What is the best way to evaluate 
and investigate patients with 
hypertriglyceridaemia?
Once hypertriglyceridaemia has been recognised, the evaluation 
focuses on identifying secondary factors and assessing the risk of 
acute pancreatitis or CVD. The majority of hypertriglyceridaemic 
patients seen in routine clinical practice have identifiable secondary 
factors that might have precipitated new or exacerbated pre-existing 
hypertriglyceridaemia. A careful dietary history should be taken, 
focusing particularly on alcohol intake, fat consumption and 
refined carbohydrate intake. Collateral history may be particularly 
helpful when assessing alcohol intake. All medication should 
be reviewed, including over-the-counter drugs. It is particularly 
important to enquire specifically about oral contraceptives and 
other hormonal preparations, as many patients do not regard 
these as ‘medicine’. A family history is also useful and may help to 
assess the risk of CVD and diabetes. Useful baseline investigations 
include a fasting glucose, HbA1C (if appropriate), creatinine, urine 
dipstick and thyroid-stimulating hormone (TSH). Depending on 
the clinical situation, liver function testing may be useful to screen 
for non-alcoholic fatty liver disease. Specialised lipid testing may 
include agarose gel electrophoresis, gradient gel electrophoresis and 
determination of apo B and apo A1. The latter investigations should 
generally be performed at the specialist level, as they are not always 
straightforward to interpret. Genetic testing plays a minor role in 
the management of most hypertriglyceridaemic patients and should 
only be done at a specialist lipid clinic.
There are no algorithms to formally quantify the risk of acute 
pancreatitis, which is increased in patients with previous pancreatitis 
and in alcohol users. The risk also increases with the severity 
of hypertriglyceridaemia, although the correlation is imperfect. 
Practically, defining all patients with TGs >10.0 mmol/L as ‘at risk’ 
for acute pancreatitis, is a good policy to ensure rapid assessment 
and treatment. Cardiovascular risk is assessed using standard 
clinical guidelines; patients with diabetes and established CVD 
are classified as very high risk without needing risk calculation. 
For other patients, risk is quantified using an algorithm such 
as the Framingham charts. These charts, unfortunately, do not 
incorporate TGs and may thus underestimate risk in some patients 
with hypertriglyceridaemia.
How should patients with 
hypertriglyceridaemia be managed?
For patients with severe hypertriglyceridaemia, the initial focus is on 
the prevention of acute pancreatitis, and they should be seen urgently. 
Any identified secondary factors should be addressed and removed 
whenever possible. This may include discontinuing and replacing 
potentially precipitating medications such as corticosteroids, 
Fig. 1. Clinical signs in hypertriglyceridaemia. (A) Eruptive xanthomata. (B) Tubo-eruptive xanthomata. (C) Lipaemic plasma.
A           B                             C
Table 1. Secondary causes of hypertriglyceridaemia
Medical disorders
Type 2 diabetes/metabolic syndrome
Hypothyroidism
Renal failure
Systemic lupus erythematosus
Paraproteinaemia (rare)
Lifestyle
Obesity
Increased alcohol consumption
Diet (excess energy, high fat, high glycaemic index)
Medication
Corticosteroids
Retinoids
Oestrogen (especially when given orally)
Tamoxifen
Protease inhibitors (the risk is highest with ritonavir) 
Cholestyramine
Leflunomide
Second-generation antipsychotics
Cyclosporin
Sirolimus
Thiazides
Beta-blockers
Other
Pregnancy (in susceptible individuals)
Auto-immune states
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retinoids or oestrogen-containing preparations when possible to do 
so. Patients should be advised not to consume alcohol. Improving 
glycaemic control is an important intervention and, in many 
patients, it is best and most rapidly achieved either by starting 
insulin or by intensifying insulin therapy. Dietary restriction 
of TG intake is very important in most patients with severe 
hypertriglyceridaemia because poor clearance of TGRL is usually 
an important component of the pathophysiology. Reducing dietary 
TG intake reduces the formation of chylomicrons in the intestine 
and also results in less TG delivery to the liver for incorporation 
into very low-density lipoproteins (VLDL). Patients with severe 
hypertriglyceridaemia are often prescribed a diet that is extremely 
low in dietary fat (‘rescue diet’: <10.0 g of fat per day). Such 
a diet is not sustainable in the long term, but can lower TGs 
relatively acutely over a few days. In the long term most patients 
are maintained on a very low-fat diet (20 - 30 g of dietary fat per 
day/~20% of caloric intake from fat), but the diet can be modified 
later according to the patient’s response and underlying conditions. 
When referring patients for dietary advice, it is important to 
specifically request that they not be given a Therapeutic Lifestyle 
Diet, but that the focus needs to be on reducing dietary fat from 
all sources. In patients with hypertriglyceridaemia there are no 
‘good’ or ‘bad’ dietary fats, as all dietary fats (except for special 
preparations containing medium-chain TGs) are incorporated into 
chylomicrons and thus contribute to raising serum TGs. For severe 
hypertriglyceridaemia, fibrates are the most effective drugs, except 
for patients with monogenic hypertriglyceridaemia, in whom they 
are usually not effective. In SA, bezafibrate and fenofibrate are the 
best-known fibrates. These drugs are generally well tolerated, but 
because they are renally excreted the dose needs to be adjusted in 
patients with chronic kidney disease. Fibrates can be combined 
with statins, but this should be done with caution and specialist 
review is usually worthwhile when considering a statin and fibrate 
combination. Gemfibrozil should not be combined with a statin 
because of the risk of drug-drug interactions. Statins are not 
effective in patients with severe hypertriglyceridaemia, even if 
prescribed at maximal doses. Using statins as the primary agent in 
patients with severe hypertriglyceridaemia is a relatively common 
mistake, because the very high total cholesterol in cases of severe 
hypertriglyceridaemia (e.g. a total cholesterol of 30.0 mmol/L in a 
patient with a TG of 70.0 mmol/L) often becomes a misleading focal 
point. As the concentration of TGRL falls with treatment, the total 
cholesterol will decrease. 
In patients with mild-to-moderate hypertriglyceridaemia, the 
initial focus is on cardiovascular risk assessment and risk reduction. 
Very high-risk and high-risk patients require medication in 
addition to lifestyle modification. Statins are generally the drugs of 
first choice to reduce cardiovascular risk in patients with mild-to-
moderate hypertriglyceridaemia. The statin dose should be adjusted 
to achieve the guideline-recommended LDL cholesterol target.[7] 
Non-HDL cholesterol (or apo B) is an important secondary target in 
patients with hypertriglyceridaemia because it reflects the presence 
of remnant cholesterol – consider intensifying therapy in patients 
with LDL cholesterol at target but non-HDL cholesterol above 
target (the target for non-HDL cholesterol is always 0.8 mmol/L 
above the relevant LDL cholesterol target). Important lifestyle 
interventions include reducing body weight, reducing alcohol 
intake, reducing simple sugar intake, increasing activity, replacing 
trans and saturated fats with monounsaturated fats and increasing 
dietary omega-3 fatty acids. 
Should additional therapy be added 
to a statin to reduce cardiovascular 
risk further in patients with 
hypertriglyceridaemia? 
This is currently the source of much debate, and much confusion 
ensues from different guidelines giving differing advice. There 
is clinical equipoise, as demonstrated by the approval of several 
ongoing double-blind placebo-controlled cardiovascular outcomes 
studies that are evaluating the addition of omega-3 fatty acids (two 
studies) or a novel fibrate (one study) to statin-treated patients 
with residual hypertriglyceridaemia and low HDL cholesterol. 
Retrospective analyses of fibrate monotherapy studies and a 
subanalysis of the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD)  study[8] (in which fenofibrate or placebo was added to 
the regimen of diabetic patients treated with simvastatin) suggest 
that fibrates may improve cardiovascular outcomes in patients with 
TGs >2.3 mmol/L and low HDL cholesterol. Based on the results of 
the ACCORD study, the European Society of Cardiology/European 
Atherosclerosis Society (ESC/EAS) guidelines (on which the South 
African lipid guidelines are based) (https://www.eas-society.org/) 
state that addition of fenofibrate to statin-based therapy can be 
considered in high-risk patients with TGs >2.3 mmol/L (class IIB, 
level C).[7] Once the results of the statin and ‘second agent’ outcome 
studies are available, the management of hypertriglyceridaemia 
in high cardiovascular risk patients will hopefully become much 
clearer and more evidence based. For now, the emphasis remains on 
prescribing an adequate statin dose, control of other cardiovascular 
risk factors and intensive lifestyle modifications. Further information 
on this topic is available at the website of the Residual Risk Reduction 
Initiative (http://www.r3i.org/) or the National Lipid Association 
(https://www.lipid.org).
What novel therapies are in the pipeline? 
The two most promising and advanced novel strategies focus on the 
inhibition of proteins that interfere with the action of LPL. Lipoprotein 
lipase (LPL) is directly inhibited by apo C3. Volanesorsen is an 
antisense oligonucleotide that reduces apo C3 protein production. 
Encouraging early results have been seen in patients with LPL 
deficiency and other forms of hypertriglyceridaemia.[9] Angiopoietin-
like 3 (ANGPTL-3) is secreted by the liver and also inhibits LPL, 
particularly after a meal. Monoclonal antibodies against ANGPTL3 
are currently in early-phase clinical trials.[10] 
Conclusion
Our understanding of the metabolism and clinical role of TGRLs has 
improved significantly over the past few years. This research has led 
to the identification of several new and exciting potential therapeutic 
targets. However, the major challenge in the next few years remains to 
define how we should optimally use currently available therapies such 
as fibrates or omega-3 fatty acids in patients with mild-to-moderate 
hypertriglyceridaemia and high cardiovascular risk.
Summary 
• Severe hypertriglyceridaemia (>10.0 mmol/L) can trigger acute 
pancreatitis.
• A precipitating factor (most commonly uncontrolled or undiag-
nosed type 2 diabetes mellitus or medication) is present in most 
patients with severe hypertriglyceridaemia.
• Mild-to-moderate hypertriglyceridaemia (1.7 - 10.0 mmol/L) is an 
independent cardiovascular risk factor.
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• Currently, it is not clear whether a second agent should be 
added in high cardiovascular risk patients with mild-to-moderate 
hypertriglyceridaemia, who are being treated with optimised statin 
therapy. 
• Fibrates are the drugs of choice in patients with severe hyper-
triglyceridaemia.
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